First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

A South African Hero: You

There’s a 99.7% chance that this isn’t for you. Only 0.3% of our readers have responded to this call for action.

Those 0.3% of our readers are our hidden heroes, who are fuelling our work and impacting the lives of every South African in doing so. They’re the people who contribute to keep Daily Maverick free for all, including you.

We need so many more of our readers to join them. The equation is quite simple: the more members we have, the more reporting and investigations we can do, and the greater the impact on the country. We are inundated with tip-offs; we know where to look and what to do with the information when we have it – we just need the means to help us keep doing this work.

Be part of that 0.3%. Be a Maverick. Be a Maverick Insider.

Support Daily Maverick→
Payment options

Pfizer study to vaccinate whole Brazilian town against...

Newsdeck

Newsdeck

Pfizer study to vaccinate whole Brazilian town against Covid-19

A senior receives the CoronaVac vaccination shot at a drive-thru vaccination post at the Rio de Janeiro State University (UERJ) on February 1, 2021 in Rio de Janeiro, Brazil. The city of Rio de Janeiro started today a priority vaccination program against COVID-19 in elderly people over 99 years old. Immunization is being carried out in 236 clinics, in addition to posts using the drive-thru system. The CoronaVac vaccine was developed by the Chinese laboratory Sinovac in partnership with the Butantan Institute. (Photo by Buda Mendes/Getty Images)
By Reuters
07 Oct 2021 0

BRASILIA, Oct 6 (Reuters) - Pfizer Inc will study the effectiveness of its vaccine against Covid-19 by inoculating the entire population over the age of 12 in a town in southern Brazil, the company said on Wednesday.

The study will be conducted in Toledo, population 143,000, in the west of Parana state, together with Brazil’s National Vaccination Program, local health authorities, a hospital and a federal university.

Pfizer, which developed the vaccine with German partner BioNTech SE, said the purpose was to study transmission of the coronavirus in a “real-life scenario” after the population has been vaccinated.

“The initiative is the first and only of its kind to be undertaken in collaboration with the pharmaceutical company in a developing country,” Pfizer said.

A similar study was conducted by the Butantan Institute, one of Brazil’s leading biomedical research centers, in the smaller town of Serrana, in Sao Paulo state. That trial tested the CoronaVac shot developed by China’s Sinovac Biotech Ltd.

In May, Butantan said mass vaccination had reduced COVID-19 death by 95% in the town with a population of 45,644 people. The institute is considering extending the study for a third dose.

“Here we believe in science and we lament the almost 600,000 deaths from COVID-19 in Brazil,” Toledo Mayor Beto Lunitti said at a news conference announcing the Pfizer study.

There is little anti-vaccine resistance in Toledo, where 98% of the population have had a first dose, mainly of the Pfizer/BioNTech vaccine. AstraZeneca’s COVID-19 shot and Sinovac’s have also been used there, municipal health secretary Gabriela Kucharski said, adding that 56% are fully vaccinated.

Regis Goulart, a researcher at Porto Alegre’s Moinhos de Vento Hospital taking part in the study, said its aim was to validate the real-world efficacy and safety of the vaccine seen in clinical trials.

The observational study also will provide an opportunity to do long-term monitoring for up to one year of participants, helping to answer lingering questions such as the duration of vaccine protection against COVID-19 and new virus variants, Goulart said. (Reporting by Anthony Boadle; Editing by Jason Neely, Mark Porter and Bill Berkrot)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery

Please peer review 3 community comments before your comment can be posted